Global X S&P Biotech ETF vs VanEck Global Healthcare Leaders ETF
Overlap is estimated from the funds' listed top holdings, not their full constituent lists. Where there are no shared listed holdings it is shown as not reliably estimable.
CURE and HLTH are both Thematic ETFs. CURE tracks the S&P Biotechnology Select Industry Index and HLTH tracks the Nasdaq Global Healthcare Index. CURE has the lower management fee (0.45% vs 0.57% p.a.). Holdings overlap is approximately 9% estimated (top 50 holdings).
Global X S&P Biotech ETF
Global X
VanEck Global Healthcare Leaders ETF
VanEck
Comparison scores reflect how each ETF compares to the other on these specific dimensions only. They are not absolute ratings or recommendations.
Key differences at a glance
Neither CURE nor HLTH is the "right" pick for everyone; it comes down to what you want from the holding. Where they differ most:
Category scores compare these two ETFs only and are not absolute ratings.
CURE has the lower management fee - the one objective "cheaper" axis.
HLTH is the larger fund. Larger is not inherently better, but greater scale can support tighter spreads and lower closure risk.
CURE spreads exposure across more holdings (CURE 143, HLTH 50); the other is more concentrated. Neither is inherently better - it depends on whether you want breadth or a focused tilt.
CURE distributes approximately 0.8% and HLTH approximately 0.6%; CURE carries the higher estimated distribution yield. A higher yield may suit an income focus; a lower one may suit a growth or tax-efficiency focus. Yields are estimates and are not guaranteed; past performance is not a reliable indicator of future returns.
Green highlights the factually lower fee or higher scale/income figure. Performance is never highlighted. Data from issuer disclosures, reviewed quarterly.
Yield figures are estimates based on recent distributions and may vary. Past distributions are not a reliable indicator of future distributions.
Past performance is not a reliable indicator of future returns.
Top shared holdings ranked by overlap contribution, the smaller of each company's weight in the two funds. Basis: top 50 holdings.
Top 10 listed holdings for each fund, from issuer disclosures.
CURE top holdings
HLTH top holdings
Based on each fund's most recently published sector and geographic weightings; figures are approximate. Full breakdowns are shown below.
CURE sectors
HLTH sectors
CURE geography
HLTH geography
Whether CURE or HLTH fits comes down to your goals, time horizon and what you already hold. The clearest differences are summarised near the top of this page, with the full data below.
CURE and HLTH have approximately 9% estimated holdings overlap (top 50 holdings). This is considered low overlap, estimated from listed top holdings rather than the full constituent lists.
CURE has the lower management fee. CURE charges 0.45% per year ($45 per year on a $10,000 investment) and HLTH charges 0.57% per year ($57 per year on a $10,000 investment). The difference is $12 per year per $10,000 invested.
CURE (Global X S&P Biotech ETF) manages approximately $40.3M and HLTH (VanEck Global Healthcare Leaders ETF) manages approximately $49.2M. Fund size can affect liquidity and bid-ask spreads but does not by itself change the management fee.
You can hold both, but with approximately 9% estimated holdings overlap the two funds hold mostly different companies, so they can be more complementary. Whether that suits you depends on your own objectives.
There is no universally right choice. It depends on your goals, time horizon and existing holdings. CURE charges 0.45% and HLTH charges 0.57%, so CURE has the lower management fee, and they have approximately 9% estimated holdings overlap. Compare their fees, holdings and sectors above and consider each fund's Product Disclosure Statement and Target Market Determination.
General information only. This comparison and the ETFLens tools on this page provide general information about two exchange-traded funds and do not take into account your personal objectives, financial situation or needs. It is not personal financial product or investment advice. ETFLens does not hold an Australian Financial Services Licence (AFSL). Holdings overlap is calculated from each fund's published holdings (full lists where the issuer publishes one, listed top holdings otherwise), and fee data is sourced from fund manager PDS documents and updated quarterly. Past performance is not a reliable indicator of future returns. Consider each fund's Product Disclosure Statement (PDS) and Target Market Determination (TMD), and seek advice from a registered tax agent or licensed financial adviser, before making investment decisions.
Check your portfolio overlap
See how these ETFs interact with your other holdings.
Open overlap checker →Build your portfolio
ProModel a portfolio with these ETFs and see projected fees and income.
Build a portfolio →View full ETF profiles
Holdings, fees, sectors and distributions for each fund.
CURE full profile →HLTH full profile →Compare another pair
Enter any two ASX ETF tickers to see their side-by-side comparison.
Compare other ETFs →